< back to search

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.

Landewe, R   •   Braun, J   •   Deodhar, A   •   Dougados, M   •   Maksymowych, W P   •   Mease, P J   •   Reveille, J D   •   Rudwaleit, M   •   van der Heijde, D   •   Stach, C   •   Hoepken, B   •   Fichtner, A   •   Coteur, G   •   de Longueville, M   •   Sieper, J

published in: Annals of the rheumatic diseases



endpoint

Certolizumab pegol has (optional: compared with placebo) proved to be better.
general condition better


basics

diagnosis:
ankylosing spondylitis

localization:
not specified

method:
conservative therapy → injection therapy
conservative therapy → injection therapy
conservative therapy → injection

publication details

10.1136/annrheumdis-2013-204231
pubmed
24013647
2014
randomized controlled trial
yes
prospective
1+

▼
▲